MERUS N.V. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 45.04 USD | +0.24% |
|
+13.14% | +63.78% |
| Apr. 19 | Gilead Sciences Likely to Record IPR&D Hit on Q1 Non-GAAP Earnings, Oppenheimer Says | MT |
| Mar. 28 | Truist Securities Initiates Coverage on Merus With Buy Rating, $69 Price Target | MT |
ETFs positioned on Merus N.V.
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.11% | 2 M€ | -.--% | ||
| 0.07% | 0 M€ | 0.00% | - | |
| 0.06% | 0 M€ | 0.00% | - | |
| 0.04% | 7 M€ | -.--% | - | |
| 0.02% | 773 M€ | -.--% | - | |
| 0.01% | 9 M€ | -.--% | - |
Merus NV is the Netherlands - based biotechnology company, concentrated on developing differentiating therapeutics for cancer patients. The product programs in the Merus pipeline are based on the Multiclonics format. Its products are designed to bind to multiple targets, and are manufactured with features for anti-cancer effects against the complex mechanisms that drive cancer. Company's products engage cancer antigens and harness the power of the immune system to kill tumor cells by utilizing technology platform. One of the drug zenocutuzumab (Zeno), a Biclonics antibody, concentrates on helping patients with lung, pancreatic and other types of solid tumors. The company operates in the Netherlands and United States.
Calendar
2024-05-05
- Q1 2024 Earnings Release (Projected)
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
BUY
Number of Analysts
13
Last Close Price
45.04
USD
Average target price
60.45
USD
Spread / Average Target
+34.22%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +63.78% | 2.64B | |
| -2.31% | 103B | |
| +0.56% | 95.28B | |
| +1.69% | 22.15B | |
| -17.37% | 21.02B | |
| -9.30% | 18.15B | |
| -41.01% | 16.73B | |
| -14.85% | 16.05B | |
| +3.21% | 13.68B | |
| +33.54% | 12.17B |
- Stock Market
- Equities
- MRUS Stock
- Funds and ETFs Merus N.V.
